McKesson Corporation (NYSE:MCK) Files An 8-K Results of Operations and Financial Condition

McKesson Corporation (NYSE:MCK) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

Story continues below

On May24, 2018, McKesson Corporation (the “Company”) announced via press release the Company’s preliminary results for the fourth quarter and fiscal year ended on March31, 2018. A copy of the Company’s press release is attached hereto as Exhibit99.1.

The information contained in this Form8-K, including Exhibit99.1, is furnished to the Securities and Exchange Commission (the “Commission”), but shall not be deemed “filed” with the Commission for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such a filing.

Item 2.02 Financial Statements and Exhibits.

(d) Exhibits.


MCKESSON CORP Exhibit
EX-99.1 2 d576052dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   McKESSON REPORTS FISCAL 2018 FOURTH-QUARTER AND FULL-YEAR RESULTS     •   Revenues of $51.6 billion for the fourth quarter and $208.4 billion for the full year.     •   Fourth-quarter GAAP loss per diluted share from continuing operations of $(5.58) and full-year GAAP earnings per diluted share from continuing operations of $0.30.     •   Fourth-quarter Adjusted Earnings per diluted share of $3.49 and full-year Adjusted Earnings per diluted share of $12.62.     •   Fiscal 2018 cash flow from operations of $4.3 billion.     •   The Board of Directors authorized an additional $4.0 billion share repurchase program.     •   Fiscal 2019 Outlook: Adjusted Earnings of $13.00 to $13.80 per diluted share. SAN FRANCISCO,…
To view the full exhibit click here

About McKesson Corporation (NYSE:MCK)

McKesson Corporation (McKesson) is engaged in delivering pharmaceuticals, medical supplies and healthcare information technology. The Company operates through two segments: McKesson Distribution Solutions and Technology Solutions. The McKesson Distribution Solutions segment distributes drugs and equipment, and health and beauty care products across North America and internationally. The Distribution Solutions segment provides pharmaceutical solutions for biotech and pharmaceutical manufacturers, and practice management, technology, clinical support and business solutions to oncology and other specialty practices operating in the community setting. The Technology Solutions segment delivers clinical, patient care, financial, supply chain and strategic management software solutions, as well as connectivity, outsourcing and other services. Its McKesson Health Solutions portfolio includes ClarityQx, which is a payment technology.

An ad to help with our costs